CTLA4 and neoplasm: Therefore, the effects of anti-CTLA-4 ICI and CRT-NPs on CRC tumor progression were analyzed as monotherapies, respectively, as well as in combination therapy to enhance the translatability of ICI use in patients, and potentially reduce their dose-dependent toxicities.